These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 34512500)

  • 1. Clinical and Paraclinical Biomarkers and the Hitches to Assess Conversion to Secondary Progressive Multiple Sclerosis: A Systematic Review.
    Krajnc N; Bsteh G; Berger T
    Front Neurol; 2021; 12():666868. PubMed ID: 34512500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals.
    Boyko A; Therapontos C; Horakova D; Szilasiová J; Kalniņa J; Kolontareva J; Gross-Paju K; Selmaj K; Sereike I; Milo R; Gabelić T; Rot U
    Mult Scler Relat Disord; 2021 May; 50():102778. PubMed ID: 33592384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early diagnosis of secondary progressive multiple sclerosis: focus on fluid and neurophysiological biomarkers.
    Ferrazzano G; Crisafulli SG; Baione V; Tartaglia M; Cortese A; Frontoni M; Altieri M; Pauri F; Millefiorini E; Conte A
    J Neurol; 2021 Oct; 268(10):3626-3645. PubMed ID: 32504180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Progress in the Identification of Early Transition Biomarkers from Relapsing-Remitting to Progressive Multiple Sclerosis.
    Maier S; Barcutean L; Andone S; Manu D; Sarmasan E; Bajko Z; Balasa R
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
    Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
    Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary Progressive Multiple Sclerosis: New Insights.
    Cree BAC; Arnold DL; Chataway J; Chitnis T; Fox RJ; Pozo Ramajo A; Murphy N; Lassmann H
    Neurology; 2021 Aug; 97(8):378-388. PubMed ID: 34088878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary progressive multiple sclerosis - from neuropathology to definition and effective treatment.
    Adamczyk-Sowa M; Adamczyk B; Kułakowska A; Rejdak K; Nowacki P
    Neurol Neurochir Pol; 2020; 54(5):384-398. PubMed ID: 33058113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of cytotoxic Eomes-expressing CD4
    Raveney BJE; Sato W; Takewaki D; Zhang C; Kanazawa T; Lin Y; Okamoto T; Araki M; Kimura Y; Sato N; Sano T; Saito Y; Oki S; Yamamura T
    Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33836594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and diagnosis of Secondary Progressive Multiple Sclerosis during the clinical encounter: Results from a physician survey.
    Alvarez E; Nair KV; Gorritz M; Bartolome L; Maloney H; Ding Y; Golan T; Wade RL; Kumar R; Su W; Shah R; Russo P
    Mult Scler Relat Disord; 2021 May; 50():102858. PubMed ID: 33799068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis.
    Lizak N; Malpas CB; Sharmin S; Havrdova EK; Horakova D; Izquierdo G; Eichau S; Lugaresi A; Duquette P; Girard M; Prat A; Larochelle C; Trojano M; Grand'Maison F; Grammond P; Sola P; Ferraro D; Hupperts R; Bergamaschi R; Boz C; Van Pesch V; Spitaleri D; Terzi M; Kalincik T;
    JAMA Neurol; 2020 Nov; 77(11):1398-1407. PubMed ID: 32716480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition.
    Inojosa H; Proschmann U; Akgün K; Ziemssen T
    J Neurol; 2021 Apr; 268(4):1210-1221. PubMed ID: 31363847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis.
    Sellebjerg F; Cadavid D; Steiner D; Villar LM; Reynolds R; Mikol D
    Ther Adv Neurol Disord; 2016 Jan; 9(1):31-43. PubMed ID: 26788129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis.
    Muris AH; Rolf L; Broen K; Hupperts R; Damoiseaux J; Smolders J
    J Steroid Biochem Mol Biol; 2016 Nov; 164():254-257. PubMed ID: 26598277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [MSProDiscuss - Development of a Digital Anamnesis Tool to Identify Disease Progression in Multiple Sclerosis].
    Inojosa H; Akgün K; Haacke K; Ziemssen T
    Fortschr Neurol Psychiatr; 2021 Jul; 89(7-08):374-381. PubMed ID: 33723837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis.
    Genovese AV; Hagemeier J; Bergsland N; Jakimovski D; Dwyer MG; Ramasamy DP; Lizarraga AA; Hojnacki D; Kolb C; Weinstock-Guttman B; Zivadinov R
    Radiology; 2019 Nov; 293(2):424-433. PubMed ID: 31549947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.
    Nandoskar A; Raffel J; Scalfari AS; Friede T; Nicholas RS
    Drugs; 2017 May; 77(8):885-910. PubMed ID: 28429241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials.
    Bates D
    Neurology; 2011 Jan; 76(1 Suppl 1):S14-25. PubMed ID: 21205678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo evidence of oxidative stress in brains of patients with progressive multiple sclerosis.
    Choi IY; Lee P; Adany P; Hughes AJ; Belliston S; Denney DR; Lynch SG
    Mult Scler; 2018 Jul; 24(8):1029-1038. PubMed ID: 28569645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cervical cord area is associated with infratentorial grey and white matter volume predominantly in relapsing-remitting multiple sclerosis: A study using semi-automated cord volumetry and voxel-based morphometry.
    Bellenberg B; Schneider R; Weiler F; Suchan B; Haghikia A; Hoffjan S; Gold R; Köster O; Lukas C
    Mult Scler Relat Disord; 2015 May; 4(3):264-72. PubMed ID: 26008944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.